- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03742869
HPV Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma
November 13, 2018 updated by: Lei Li
A Multi-omics Study on the Human Papillomavirus Integration and Tumorigenesis of Uterine Cervical Adenocarcinoma
This study aims to analyze the multi-omics results between uterine cervical adenocarcinoma patients with and without human papillomavirus (HPV) infections.
The multi-omics profiles include genome wide association study (GWAS), whole exome sequencing, analysis of transcriptomics and metabolomics.
The HPV integration status is interpreted by GWAS.
A comprehensive multi-omics will reveal the role of HPV integration in the molecular mechanism of tumorigenesis and prognosis of uterine cervical adenocarcinoma.
Study Overview
Status
Unknown
Conditions
Intervention / Treatment
Study Type
Observational
Enrollment (Anticipated)
40
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Beijing
-
Beijing, Beijing, China, 100730
- Recruiting
- Lei Li
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
No
Genders Eligible for Study
Female
Sampling Method
Non-Probability Sample
Study Population
All patients confirmed primary adenocarcinoma of the uterine cervix
Description
Inclusion Criteria:
- Confirmed primary adenocarcinoma of the uterine cervix
- Signed an approved informed consents
- Feasible for biopsy
Exclusion Criteria:
- Not meeting all of the inclusion criteria
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
---|---|
Patients with HPV integration
The HPV integration status will be checked by GWAS.
|
A multi-omics analysis including genome-wide association study, whole exome sequencing, transcriptomics and metabolomics.
|
Patients without HPV integration
The HPV integration status will be checked by GWAS.
|
A multi-omics analysis including genome-wide association study, whole exome sequencing, transcriptomics and metabolomics.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Frequencies of somatic driving mutations
Time Frame: Two years
|
The differences of frequencies of somatic driving mutations will be compared between patients with and without HPV integration.
|
Two years
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Progression-free survival
Time Frame: Five years
|
Progression-free survival between patients with differential expressed multi-omics will be compared.
|
Five years
|
Frequencies of alteration of RNA expression
Time Frame: Two years
|
The alteration of patterns of RNA expression, including mRNA, miRNA, and lncRNA, will be compared between patients with and without HPV integration.
|
Two years
|
Frequencies of alteration of protein expression and signal pathway
Time Frame: Two years
|
The alteration of patterns of protein expression and signal pathway will be compared between patients with and without HPV integration.
|
Two years
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 10, 2018
Primary Completion (Anticipated)
November 23, 2021
Study Completion (Anticipated)
November 23, 2021
Study Registration Dates
First Submitted
November 9, 2018
First Submitted That Met QC Criteria
November 13, 2018
First Posted (Actual)
November 15, 2018
Study Record Updates
Last Update Posted (Actual)
November 15, 2018
Last Update Submitted That Met QC Criteria
November 13, 2018
Last Verified
November 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HITA
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
YES
IPD Plan Description
All data will be available to all researchers.
IPD Sharing Time Frame
All data will be available to all researchers once related papers have been accepted publicly, and will be available for ever.
IPD Sharing Supporting Information Type
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cervical Adenocarcinoma
-
Catalysis SLCompletedCervical Carcinoma Stage II | Cervical Carcinoma Stage III | Cervical Carcinoma Stage IV | Endometrial Adenocarcinoma Stage II | Endometrial Adenocarcinoma Stage III | Endometrial Adenocarcinoma Stage IVCuba
-
Merck Sharp & Dohme LLCCompletedPrevention of HPV Types 16- and 18-related Cervical Cancer, Cervical Intraepithelial Neoplasia (CIN) 1/2/3, and Cervical Adenocarcinoma in SituChina
-
Institut de Cancérologie de LorraineCompletedCervical Adenocarcinoma | Stage IB Cervical Cancer | Stage III Cervical Cancer | Stage II Cervical CancerFrance
-
Tampere University HospitalKarolinska Institutet; Tampere University; European UnionEnrolling by invitationCervical Intraepithelial Neoplasia Grade 2/3 | Adenocarcinoma in SituFinland
-
Shanghai Gynecologic Oncology GroupFudan UniversityCompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Malignant Neoplasm of Cervix Stage IB1 | Stage IIA1 Cervical CancerChina
-
Merck Sharp & Dohme LLCCompletedCervical Cancer | Cervical Intraepithelial Neoplasia | Adenocarcinoma in Situ
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical Cancer | Stage IVB Cervical CancerUnited States
-
Gynecologic Oncology GroupNational Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IB Cervical Cancer | Stage IIA Cervical Cancer | Stage IIB Cervical Cancer | Stage III Cervical Cancer | Stage IVA Cervical CancerUnited States
-
National Cancer Institute (NCI)CompletedCervical Adenocarcinoma | Cervical Squamous Cell Carcinoma | Stage IVA Cervical Cancer AJCC v6 and v7 | Recurrent Cervical Carcinoma | Human Papillomavirus Infection | Stage IVB Cervical Cancer AJCC v6 and v7United States, Canada
-
National Cancer Institute (NCI)TerminatedCervical Adenocarcinoma | Cervical Adenosquamous Carcinoma | Cervical Carcinoma | Cervical Carcinoma, Non-SquamousTypeUnited States
Clinical Trials on A multi-omics analysis
-
Lei LiUnknownEndometriosis | Adenomyosis | Genomics | Metabolomics | Ectopic Endometrium | Eutopic Endometrium | TranscriptomicsChina
-
Lei LiUnknownEpithelial Ovarian Cancer | Metabolomics | Transcriptomics | Whole Exome Sequencing | Tumor Invasiveness | TumorigenesisChina
-
Qilu Hospital of Shandong UniversityNot yet recruiting
-
The First Affiliated Hospital with Nanjing Medical...Recruiting
-
Capital Medical UniversityRecruitingSevere Community-acquired PneumoniaChina
-
GeneCast Biotechnology Co., Ltd.Cancer Institute and Hospital, Chinese Academy of Medical SciencesRecruitingGastric CancerChina
-
Zhejiang Cancer HospitalSun Yat-sen University; Shanghai Zhongshan Hospital; Fujian Cancer Hospital; RenJi... and other collaboratorsRecruitingMalignant Tumors of Digestive TractChina
-
University Hospital TuebingenRecruiting
-
Fudan UniversityUnknownColorectal Cancer Metastatic
-
Peking University Third HospitalPeking UniversityRecruitingHeart Failure | Percutaneous Coronary Intervention | Cardiometabolic Syndrome | Structural Heart AbnormalityChina